City of Hope | Strategic Alliance Partners

May 25, 2016

Sumanta Kumar Pal, MD, provides insight on the FDA approval of the TKI lenvatinib in combination with everolimus, an mTOR inhibitor as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

May 19, 2016

Shouldn’t the goal of oncologists be to do what is best for their patients, regardless of the currently existing level of evidence and particularly when any timeline for obtaining that "gold standard" evidence will be irrelevant for the patient being cared for today?

May 03, 2016

If germline testing for a cancer-associated purpose reveals the risk of an unrelated illness like Alzheimer disease, should patients routinely be told—even if there’s nothing that can be done about that “incidental” finding?

April 26, 2016

The research will test how 8-chloro-adenosine functions in patients with refractory/relapsed AML.

March 14, 2016

The collaboration will bring together exceptional researchers from the United States and Israel.

February 26, 2016

The study calls for changes to reduce health disparities.

February 11, 2016

Although the goals of quality-care and value-based oncology initiatives are legitimate and laudable, some of the assertions should be examined more closely.

January 15, 2016

Thoracic specialist will guide expansion of clinical programs, integrate research into patient care.

January 12, 2016

City of Hope is offering an interactive educational conference for oncologists, hematologists and oncology nurses to learn about the latest advances in bone marrow transplants, as well as the treatment of leukemia, lymphoma and myeloma.

December 21, 2015

It is simply unrealistic and highly counterproductive to the future of cancer care to believe that the only acceptable approach to determining the absolute or relative clinical utility of a specific drug, regimen, device, or procedure, is through the conduct of a so-called evidence-based randomized trial.

November 05, 2015

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

October 08, 2015

Examples of the clinical relevance of an individual patient's normal polymorphisms continue to mount.

September 14, 2015

How can any analysis of the quality of cancer care being delivered by providers that focuses on a survival outcome as the ultimate measure of that quality-rather than on an evaluation of the optimization of the care process-be considered objectively valid and clinically meaningful?

June 22, 2015

Maurie Markman, MD, discusses how the molecular complexities of cancer necessitate that clinical research evolves beyond the basket trial design.

June 09, 2015

The past decade has demonstrated a movement toward more extensive LND in order to sample and remove more lymph nodes.

May 27, 2015

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

April 29, 2015

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses prostate cancer screening.

April 13, 2015

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

April 07, 2015

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

March 18, 2015

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines.